Leflunomide - a perennial question in GCA, that we still haven’t answered (as this meta-analysis shows), despite clear potential. We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF? #ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg